Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors

NCT02721732 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02721732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02721732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 15, 2016
Completion date
December 31, 2028
Enrollment
157 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, carcinoma of unknown primary, metastatic adrenal gland pheochromocytoma, metastatic kidney medullary carcinoma, metastatic malignant germ cell tumor, metastatic malignant solid neoplasm, metastatic paraganglioma, metastatic penile carcinoma, metastatic skin squamous cell carcinoma, small cell carcinoma, stage iii adrenal cortex carcinoma ajcc v7, stage iv adrenal cortex carcinoma ajcc v7, stage iv penile cancer ajcc v7, stage iv renal cell cancer ajcc v7, unresectable adrenal gland pheochromocytoma, unresectable paraganglioma, unresectable skin squamous cell carcinoma, unresectable solid neoplasm, vascular neoplasm